Thrombolytic efficacy of a Lys-plasminogen-urokinase combination: studies in experimental animals and humans

During animal experimental phase, lis-pg combined with UK produced a thrombolysis of about a 62.5%. This effect is accompanied by an important fibrinolytic system activation, a decrease in fibrinogen levels (0.37 +/- 0.2 gr/l) and an increase PDF/Fg (120.5 +/- 30 ng/ml). Such thrombolytic stage prod...

Full description

Saved in:

Bibliographic Details
Published in:	Angiologia Vol. 42; no. 6; p. 218
Main Authors:	Latorre, J, Foncuberta, J, Rosendo, A, Elez, J
Format:	Journal Article
Language:	Spanish
Published:	Spain 01-11-1990
Subjects:	Adult Animals Dogs Drug Therapy, Combination Female Follow-Up Studies Humans Male Middle Aged Peptide Fragments - therapeutic use Plasminogen - therapeutic use Thrombolytic Therapy Thrombophlebitis - blood Thrombophlebitis - drug therapy Time Factors Urokinase-Type Plasminogen Activator - therapeutic use
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	During animal experimental phase, lis-pg combined with UK produced a thrombolysis of about a 62.5%. This effect is accompanied by an important fibrinolytic system activation, a decrease in fibrinogen levels (0.37 +/- 0.2 gr/l) and an increase PDF/Fg (120.5 +/- 30 ng/ml). Such thrombolytic stage produced diverse hemorrhagic complications in experimental animals. During human clinical trial stage, then patients with Deep Venous Thrombosis (DVT) at proximal lower limbs level were submitted to diverse treatment protocols with Lis-Plasminogen (Lis-plg) and Urokinase (UK). After preliminary outcomes we can conclude that administration of Lis-plg followed by UK increases the fibrinolytic activity but also increases the risk of hemorrhagic complications. This second effect is not probably caused by an specific absorption on the thrombo surface, but by an increase of circulating plasminogen levels Lis-plg exogenous-induced.
ISSN:	0003-3170